2. Academic Validation
  3. Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids

Antibody drug conjugates of cleavable amino-alkyl and aryl maytansinoids

  • Bioorg Med Chem. 2018 May 15;26(9):2271-2279. doi: 10.1016/j.bmc.2018.02.025.
Thomas Nittoli 1,  Marcus P Kelly 2,  Frank Delfino 2,  John Rudge 2,  Arthur Kunz 2,  Thomas Markotan 3,  Jan Spink 3,  Zhaoyuan Chen 2,  Jing Shan 2,  Elizabeth Navarro 2,  Michele Tait 2,  Kathleen Provoncha 2,  Jason Giurleo 2,  Feng Zhao 2,  Xiaobo Jiang 2,  Donna Hylton 2,  Sosina Makonnen 2,  Carlos Hickey 2,  Jessica R Kirshner 2,  Gavin Thurston 2,  Nicholas Papadopoulos 2
Affiliations

Affiliations

  • 1 Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States. Electronic address: [email protected].
  • 2 Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591, United States.
  • 3 Abzena, 360 George Patterson Blvd, Bristol, PA 19007, United States.
PMID: 29605304 DOI: 10.1016/j.bmc.2018.02.025
Abstract

Natural Products have been used for many medicinal purposes for centuries. Antibody drug conjugates (ADCs) have utilized this rich source of small molecule therapeutics to produce several clinically useful treatments. ADCs based on the natural product maytansine have been successful clinically. The authors further the utility of the anti-cancer natural product maytansine by developing efficacious payloads and linker-payloads for conjugating to Antibodies. The success of our approach was realized in the EGFRvIII targeting ADC EGFRvIII-16. The ADC was able to regress tumors in 2 tumor models (U251/EGFRvIII and MMT/EGFRvIII). When compared to a positive control ADC, the efficacy observed was similar or improved while the isotype control ADCs had no effect.

Keywords

Antibody; Antibody drug conjugate; EGFRvIII; Maytansinoid.

Figures
Products